| Literature DB >> 33452107 |
Keith D Kauffman1, Shunsuke Sakai1, Nickiana E Lora1, Sivaranjani Namasivayam2, Paul J Baker3, Olena Kamenyeva4, Taylor W Foreman1, Christine E Nelson1, Deivide Oliveira-de-Souza5, Caian L Vinhaes5, Ziv Yaniv6, Cecilia S Lindestam Arleham7, Alessandro Sette7,8, Gordon J Freeman9, Rashida Moore10, Alan Sher2, Katrin D Mayer-Barber3, Bruno B Andrade5, Juraj Kabat4, Laura E Via11, Daniel L Barber12.
Abstract
Boosting immune cell function by targeting the coinhibitory receptor PD-1 may have applications in the treatment of chronic infections. Here, we examine the role of PD-1 during Mycobacterium tuberculosis (Mtb) infection of rhesus macaques. Animals treated with anti-PD-1 monoclonal antibody developed worse disease and higher granuloma bacterial loads compared with isotype control-treated monkeys. PD-1 blockade increased the number and functionality of granuloma Mtb-specific CD8 T cells. In contrast, Mtb-specific CD4 T cells in anti-PD-1-treated macaques were not increased in number or function in granulomas, expressed increased levels of CTLA-4, and exhibited reduced intralesional trafficking in live imaging studies. In granulomas of anti-PD-1-treated animals, multiple proinflammatory cytokines were elevated, and more cytokines correlated with bacterial loads, leading to the identification of a role for caspase 1 in the exacerbation of tuberculosis after PD-1 blockade. Last, increased Mtb bacterial loads after PD-1 blockade were found to associate with the composition of the intestinal microbiota before infection in individual macaques. Therefore, PD-1-mediated coinhibition is required for control of Mtb infection in macaques, perhaps because of its role in dampening detrimental inflammation and allowing for normal CD4 T cell responses.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33452107 PMCID: PMC8300572 DOI: 10.1126/sciimmunol.abf3861
Source DB: PubMed Journal: Sci Immunol ISSN: 2470-9468